MK-5172 in Combination with MK-8742 in subjects with HCV and Chronic Kidney Disease

MK-5172 in Combination with MK-8742 in subjects with HCV and Chronic Kidney Disease

Registry ID

EUCTR2013-003858-25

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Merck Sharp & Dohme Corp.

Start date

2014-02-25

Completion date

2015-09-02

Last update

2026-08-16

Conditions

• Hepatitis C

Summary

• To evaluate the efficacy of MK-5172 + MK-8742 in HCV GT1 subjects with chronic kidney disease (CKD) within the immediate treatment and the intensive PK groups. • To evaluate the safety and tolerability of MK-5172 in combination with MK-8742 in the immediate treatment group relative to the placebo treatment of the deferred treatment group.

Locations

• , , Sweden
• , , Estonia
• , , Spain
• , , Lithuania
• , , Netherlands

Related clinical trials

• Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
• Evaluation of Patients With Liver Disease
• The Australian HCV Point-of-Care Testing Program
• Project I Test: Implementing HIV Testing in Opioid Treatment Programs
• The National Australian HCV Point-of-Care Testing Program - Minimal Dataset
• The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset

View on source registry